Evidence map›Paper›PMID 29124491›Full record

ArticleJournal of community genetics2018

From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals.

Bianca M Augusto, Paige Lake, Courtney L Scherr, Fergus J Couch, Noralane M Lindor, Susan T Vadaparampil

Abstract read
In one paragraph

Article in Journal of community genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Comprehensive clinical characterization of patients withAnnals of surgical treatment and research · 2022
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bianca M AugustoDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MFC-CRISP, Tampa, FL, 33612, USA.ORCID http://orcid.org/0000-0002-4556-530X
Paige LakeDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MFC-CRISP, Tampa, FL, 33612, USA.
Courtney L ScherrDepartment of Communication Studies, Northwestern University, Evanston, IL, USA.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Noralane M LindorDepartment of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.
Susan T VadaparampilDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, MFC-CRISP, Tampa, FL, 33612, USA. susan.vadaparampil@moffitt.org.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Breast Cancer Spore CA 116201NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA116201
6 · The paper itself

Abstract

Despite ongoing research efforts to reclassify BRCA variant of uncertain significance (VUS), results for strategies to disseminate findings to genetic counselors are lacking. We disseminated results from a study on reclassification of BRCA VUS using a mailed reclassification packet including a reclassification guide, patient education aid, and patient letter template for patients/families with BRCA VUS. This study reports on genetic counselors' responses to the dissemination materials. Eligible participants (n = 1015) were identified using mailing lists from professional genetics organizations. Participants were mailed a BRCA VUS reclassification packet and a return postcard to assess responses to the materials. Closed-ended responses were analyzed using descriptive statistics, and thematic analysis was conducted on open-ended responses. In response to the mailing, 128 (13.0%) genetic counselors completed and returned postcards. The majority of respondents (n = 117; 91.4%) requested the patient letter template and patient education guides as PDFs (n = 122; 95.3%). The majority (n = 123; 96.9%) wanted an updated reclassification guide upon availability. Open-ended responses demonstrate the material was well-received; some specified they would tailor the patient letter to fit their practice and patients' needs. Participants requested additional patient and provider educational materials for use in practice. Materials communicating BRCA VUS reclassification updates were liked and were likely to be used in practice. To achieve the benefits of VUS reclassification in clinical practice, ongoing efforts are needed to continuously and effectively disseminate findings to providers and patients.

Indexed as

Genetic counselingGenetic testingHereditary cancerPatient educationVariant of uncertain significance (VUS)VUS reclassification

Identifiers

PMID29124491
PMCPMC6002306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.